3
ALL1
Diamyd Medical AB2
Engage TherapeuticsYear
3
ALL3
2020DEALS // DEV.
3
ALL1
Deals2
DevelopmentsCountry
3
ALL1
SWEDEN2
U.S.A3
ALL2
Inapplicable1
UCB Pharma S.ATherapeutic Area
3
ALL1
Endocrinology2
NeurologyStudy Phase
3
ALL2
Phase III1
Phase I/ Phase IIDeal Type
3
ALL1
Acquisition2
InapplicableProduct Type
3
ALL2
Controlled Substance1
Other Small MoleculeDosage Form
3
ALL1
Oral2
Oral InhalationLead Product
3
ALL2
Alprazolam1
Gamma-Aminobutyric AcidTarget
3
ALL1
GABA receptor2
GABAA receptorLead Product(s) : Alprazolam
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Staccato alprazolam has demonstrated the ability to rapidly terminate seizures in patients with epilepsy in two minutes or less and prevent recurrence of seizure within two hours.
Product Name : Staccato
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 03, 2020
Lead Product(s) : Alprazolam
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam
Therapeutic Area : Endocrinology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Swedish Medical Products Agency has approved an amendment to ReGenerate-1 to investigate Remygen®'s preventive effects on hypoglycaemia (severely reduced blood sugar level) in individuals with long-term type 1 diabetes.
Product Name : Remygen
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 24, 2020
Lead Product(s) : Gamma-Aminobutyric Acid,Alprazolam
Therapeutic Area : Endocrinology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Alprazolam
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : UCB Pharma S.A
Deal Size : $270.0 million
Deal Type : Acquisition
UCB Acquires Engage Therapeutics for Staccato® Alprazolam
Details : With is acquisition, UCB will have world-wide rights to Staccato[®] Alprazolam and would perform further clinical development, submission, launch and commercialization of Staccato[®] Alprazolam.
Product Name : Staccato
Product Type : Controlled Substance
Upfront Cash : $125.0 million
May 06, 2020
Lead Product(s) : Alprazolam
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : UCB Pharma S.A
Deal Size : $270.0 million
Deal Type : Acquisition